Published in Clin Pharmacol on September 02, 2013
Phase II, 2nd Line Melanoma - RAND Monotherapy | NCT00612664
Study of BMS-663513 in Patients With Advanced Cancer | NCT00309023
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | NCT00803374
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88
Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer (2014) 0.88
Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest (2015) 0.86
Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. PLoS One (2014) 0.83
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Advances in immunotherapy for melanoma management. Hum Vaccin Immunother (2016) 0.75
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clin Pharmacol (2013) 0.75
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 2.65
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol (1999) 1.95
Update on immunotherapy for melanoma. J Natl Compr Canc Netw (2006) 1.52
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res (2006) 1.45
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci (2008) 1.42
Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med (1999) 1.37
Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res (2002) 1.36
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol (2002) 1.29
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2003) 1.27
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res (2004) 1.22
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev (2008) 1.22
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther (2004) 1.10
From cancer immunosurveillance to cancer immunotherapy. Immunol Rev (2007) 1.10
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res (2001) 1.09
Targeting the immune system in cancer. Curr Pharm Biotechnol (2009) 1.04
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res (2005) 0.96
Melanoma as a model tumour for immuno-oncology. Ann Oncol (2012) 0.95
4-1BB as a therapeutic target for human disease. Adv Exp Med Biol (2009) 0.90
Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res (2008) 0.90
Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev (2007) 0.89
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol (2012) 0.89
Historical review of melanoma treatment and outcomes. Clin Dermatol (2013) 0.86
Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol (2004) 0.85
Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer (2008) 0.85
The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets (2005) 0.84
Immunotherapy of melanoma. Asia Pac J Clin Oncol (2010) 0.83
Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology (2013) 0.82
Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunother (2000) 0.79
CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses. Biomed Pharmacother (2008) 0.79
Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy (2013) 0.78
The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett (2012) 0.76
Attenuation of acetaldehyde-induced cell injury by overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene in human cardiac myocytes: role of MAP kinase signaling. J Mol Cell Cardiol (2006) 1.44
A "turn-off" SERS-based detection platform for ultrasensitive detection of thrombin based on enzymatic assays. Biosens Bioelectron (2013) 0.77
[Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi (2011) 0.75
Concise Synthesis of Taiwaniaquinol B and 5-epi-Taiwaniaquinone G. Nat Prod Commun (2015) 0.75
Peptide-capped gold nanoparticle for colorimetric immunoassay of conjugated abscisic acid. ACS Appl Mater Interfaces (2012) 0.75
Controlled assembly of gold nanoparticles through antibody recognition: study and utilizing the effect of particle size on interparticle distance. Langmuir (2013) 0.75